ELTX — Elicio Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1601485 ·
Last close
$2.80
Market Cap
$73.54M
52W High
$16.00
52W Low
$2.66
ADV30
1,211,800
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -10,602,000 | -11,823,000 | 22,689,000 | 14,948,000 | 24,126,000 |
| Dec 2025 | 0 | — | -8,842,000 | -7,718,000 | 25,862,000 | 18,563,000 | 24,226,000 |
| Sep 2025 | 0 | — | -8,045,000 | -10,083,000 | 28,284,000 | 20,611,000 | 24,468,000 |
| Jun 2025 | 0 | — | -9,676,000 | -10,561,000 | 29,528,000 | 22,088,000 | 27,694,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-38,478,000
Investing CF
$-16,000
Financing CF
$34,394,000
CapEx
$-45,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-2.78
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-233,672,000
Inventory
—
Receivables
$2,000
ST Investments
—
EBIT TTM
$-38,438,000
Pretax Income TTM
$-39,571,000
Interest Exp TTM
$1,133,000
Analysts
2
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -37,299,000 | -39,571,000 | 25,862,000 | 24,226,000 | — | -36,952,000 |
| Dec 2024 | 0 | -44,986,000 | -51,898,000 | 28,178,000 | 39,490,000 | — | -37,068,000 |
| Dec 2023 | 0 | -35,745,000 | -35,195,000 | 27,146,000 | 15,773,000 | — | -32,694,000 |
| Dec 2022 | 0 | -23,733,000 | -28,208,000 | 22,664,000 | 124,809,000 | — | -22,179,000 |
TTM Snapshot
Revenues TTM
$6,683,000
NetIncome TTM
$-52,398,000
OpCashFlow TTM
$0
Assets (Latest)
$28,178,000
Forward EPS
$-2.43
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PRRUF | IMMUTEP Ltd | $73.69M | $0.05 | — |
| ANVS | Annovis Bio, Inc. | $74.45M | $1.75 | — |
| GANX | Gain Therapeutics, Inc. | $71.66M | $1.68 | — |
| MAIA | MAIA Biotechnology, Inc. | $76.00M | $1.25 | — |
| PRNAF | ALTERITY THERAPEUTICS LTD | $76.13M | $0.35 | — |
News headlines (Yahoo Finance, 1h cache)
Elicio Therapeutics Announces Closing of $15 Million Registered Direct Offering
2026-07-06 20:05 · Yahoo
Wall Street Set to Open Higher in Thursday Trading; US Adds Only 57,000 Jobs in June
2026-07-02 13:23 · Yahoo
Another Blow For ELTX? Elicio Raises Fresh Capital Weeks After Trial Disappointment
2026-07-02 11:22 · Yahoo
Elicio Therapeutics Announces Pricing of $15 Million Registered Direct Offering
2026-07-02 04:25 · Yahoo
Elicio Therapeutics Added to Russell 2000® and Russell 3000® Indexes
2026-06-29 12:00 · Yahoo
Elicio Therapeutics Reports Multiple Complete Responses After ELI-002 7P Treatment and Subsequent Therapy with Checkpoint Inhibition in Metastatic mKRAS Pancreatic Cancer
2026-06-17 12:00 · Yahoo
This Monthly Dividend Powerhouse Is Trading at a Bargain-Bin Valuation
2026-06-16 18:00 · Yahoo
Stocks Settle Sharply Higher as US-Iran Peace Deal Spurs Optimism
2026-06-15 20:36 · Yahoo
Sector Update: Healthcare Stocks Softer Late Afternoon
2026-06-15 19:46 · Yahoo
ELTX Stock Heads For Worst Day Ever — Elicio Therapeutics' Pancreatic Cancer Data Disappoints
2026-06-15 18:50 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.